A novel treatment involving the stimulation of the vagus nerve has demonstrated long-lasting effectiveness in improving symptoms for individuals with severe and treatment-resistant depression, according to a recent study. The vagus nerve, one of the longest nerves in the body, plays a crucial role in regulating mood and emotional control by transmitting signals between the brain and major organs.
The two-year follow-up phase of the RECOVER trial, published in the International Journal of Neuropsychopharmacology, found that 69 percent of patients experienced a meaningful improvement in depressive symptoms after one year of treatment using a vagus nerve stimulation (VNS) device. Critically, over 80 percent of these patients maintained or further improved their condition through the second year.
A Novel Approach to Depression Treatment
The VNS device, implanted under the skin below the collarbone with a wire connected to the vagus nerve in the neck, functions similarly to a cardiac pacemaker. It delivers low-level electrical pulses to the nerve, which then sends signals to brain regions involved in mood regulation. Unlike traditional treatments, this method offers a drug-free approach.
For patients in the study, improvement was defined as at least a 30 percent reduction in depressive symptoms or measurable enhancements in daily functioning. A substantial benefit was considered a 50 percent reduction in symptoms. The study tracked patients over two years, assessing the durability of the benefits achieved in the first year.
Approximately 21 million adults in the U.S. experience depression, with an estimated 2.8 million to 7 million living with treatment-resistant depression (TRD). TRD affects individuals who have not found relief after trying at least two different antidepressant medications at appropriate doses and durations. These patients often have limited treatment options.
Sustained Benefits and Unexpected Improvements
Many participants in the RECOVER trial had struggled with depression for an average of 17 years and had failed more than 13 different treatments, including medications, therapy, and electroshock therapy. The study included patients who were particularly debilitated, with nearly three-quarters unable to work and over 40 percent having a history of suicide attempts.
Remarkably, even among patients who had not responded to VNS treatment by the end of the first year, approximately 30 to 38 percent showed improvement during the second year. This suggests that VNS may require a longer period to take full effect for some individuals.
By the two-year mark, more than one in five patients achieved remission, indicating their symptoms improved to a degree that allowed for normal functioning. Researchers verified that these sustained benefits were not due to increased use of medications or other therapies during the second year of the study.
Study Context and Funding
The RECOVER trial was funded by LivaNova PLC, the manufacturer of the VNS device. The company supported the study's execution, data analysis, and report drafting. Several authors of the study have reported consulting or financial ties to LivaNova, though the authors stated they had full control over the final manuscript.